092040.KQ
Amicogen, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 986.00
+2.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 46.7B | 42.0B | 173.6B | 159.9B | 144.3B |
| Cost of Revenue | 40.3B | 39.1B | 123.1B | 104.8B | 101.8B |
| Gross Profit | 6.4B | 2.9B | 50.5B | 55.1B | 42.5B |
| Operating Expenses | |||||
| R&D Expense | 5.2B | 7.4B | 12.6B | 13.8B | 12.4B |
| SG&A Expense | 7.2B | 10.8B | 17.5B | 15.4B | 35.0B |
| General & Admin Expense | 1.0B | 1.2B | 7.5B | 6.9B | 4.5B |
| Selling & Marketing Expense | 2.0B | 3.1B | 10.0B | 8.5B | 12.1B |
| Other Expenses | 8.0B | — | 27.4B | 23.8B | — |
| Total Operating Expenses | 20.4B | 18.3B | 57.5B | 53.1B | 47.4B |
| Cost and Expenses | 61.3B | 57.4B | 180.7B | 157.8B | 149.2B |
| Operating Income (EBIT) | (12.7B) | (15.4B) | (7.1B) | 2.1B | (4.9B) |
| Non-Operating | |||||
| Interest Income | 309.2M | 250.6M | 533.6M | 498.4M | 412.8M |
| Interest Expense | 6.9B | 7.8B | 10.2B | 11.3B | 7.5B |
| Net Interest Income | (6.6B) | (7.5B) | (9.7B) | (10.8B) | (7.0B) |
| Other Non-Op Income/Expense | (5.9B) | (14.5B) | (43.5B) | (25.3B) | (45.7B) |
| Non-Operating Income (excl Interest) | 4.9B | — | 33.2B | (5.3B) | 14.7B |
| EBT (Pre-Tax Income) | (18.7B) | (29.9B) | (50.5B) | (23.2B) | (50.6B) |
| Income Tax Expense | 1.4B | 491.2M | 343.3M | (2.5B) | (4.8B) |
| Bottom Line | |||||
| Net Income | (19.3B) | (30.0B) | (52.8B) | (23.3B) | (47.2B) |
| Earnings from Cont. Ops | (20.0B) | (30.4B) | (50.9B) | (20.7B) | (45.8B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.3B) | (30.0B) | (52.8B) | (23.3B) | (47.2B) |
| Per Share | |||||
| Basic EPS | (₩310) | (₩540) | (₩964) | (₩584) | (₩1,103) |
| Diluted EPS | (₩310) | (₩540) | (₩964) | (₩584) | (₩1,103) |
| Revenue Per Share | ₩662 | ₩753 | ₩3,160 | ₩4,007 | ₩3,369 |
| Shares | |||||
| Basic Shares Outstanding | 70.5M | 55.7M | 54.9M | 39.9M | 42.8M |
| Diluted Shares Outstanding | 70.5M | 55.7M | 54.9M | 39.9M | 42.8M |
| Profitability Metrics | |||||
| EBITDA | (9.0B) | (5.7B) | (26.3B) | 14.0B | (7.0B) |
| D&A | 9.2B | 9.6B | 14.0B | 13.3B | 12.7B |
| EBIT | (20.4B) | (15.4B) | (40.3B) | 689.4M | (19.6B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026